AlphaStocks
5.3
Consider Buy

Veracyte, Inc. (VCYT)

As of Sep 20, 2026, Veracyte, Inc. (VCYT) scores 5.3/10 on AlphaStocks' five-model composite, #90 of 168 Health Care stocks. At $40, VCYT trades 104% above its model fair value of $20.

Health Care / Health Care Services

S&P SmallCap 600

$39.78

Below average on several measures. Research carefully.

Consider Buy

Score based on 3 of 5 models — moderate confidence

Data as of Sep 20, 2026

#90out of 168 in Health Care

Is VERACYTE, INC. a Good Investment in 2026?

VERACYTE, INC. (VCYT) scores 5.3 out of 10 on AlphaStocks' composite model, earning a Consider Buy rating. The Piotroski model rates VERACYTE, INC. as Strong (7/9). However, the Graham model rates it Caution — Significantly above fair value. VERACYTE, INC. currently trades 104% above its estimated fair value of $20. VERACYTE, INC. ranks #90 out of 168 stocks in the Health Care sector.

This summary is algorithmically generated and is not financial advice.

Key Metrics

P/E48.3ROE3.9Market Cap3B

Estimated Fair Value

$19.52104% above

Trading above estimated fair value. P/e of 48x implies high growth expectations. rapid eps growth (167%) partially justifies the premium.

Model-based estimate, not a price target.

5-Model Analysis

Each model evaluates this stock from a different angle. Combined, they form the composite score above.

Piotroski

Strong

7/9

Buffett

Neutral

Business quality & competitive moat

Graham

Caution

Significantly above fair value

Lynch

Limited Data

Growth rate vs price (PEG)

Greenblatt

Limited Data

Earnings yield + return on capital

Frequently Asked Questions

Is VERACYTE, INC. (VCYT) a good investment?
As of Sep 20, 2026, Veracyte, Inc. (VCYT) scores 5.3/10 on AlphaStocks' five-model composite, #90 of 168 Health Care stocks. At $40, VCYT trades 104% above its model fair value of $20. That score is below average, suggesting caution.
What is VERACYTE, INC.'s Piotroski F-Score?
VERACYTE, INC.'s Piotroski F-Score status is Strong. The raw score is 7/9. The Piotroski F-Score evaluates financial health using 9 fundamental signals including profitability, leverage, and operating efficiency.
Is VCYT overvalued or undervalued?
Based on AlphaStocks' model-based fair value estimate of $20, VCYT appears overvalued. The stock currently trades 104% above its estimated fair value. Trading above estimated fair value. P/e of 48x implies high growth expectations. rapid eps growth (167%) partially justifies the premium.
How does VCYT compare to other Health Care stocks?
VERACYTE, INC. ranks #90 out of 168 stocks in the Health Care sector, placing it in the top 54% of its sector by composite score. There are higher-ranked alternatives in this sector worth exploring.
What do investment models say about VCYT?
AlphaStocks evaluates VCYT using five proven investment models. Piotroski: Strong; Buffett: Neutral; Graham: Caution. These models are combined into a single composite score of 5.3/10.

Similar Stocks

DVAMDDGX

Compare VCYT with

DVA vs VCYTMD vs VCYTDGX vs VCYT

Scores are algorithm-generated research tools, not investment recommendations. Past performance does not guarantee future results. Always do your own due diligence. Full disclaimer